Dobson|DaVanzo

Dobson | DaVanzo Publishes a Study in Advances in Wound Care

Published Thursday, March 31, 2022

Dobson | DaVanzo staff are pleased to announce a recently accepted study in Advances in Wound Care, titled, "Cryopreserved placental membrane allograft reduces the likelihood of developing a new or recurring foot ulcer and all-cause mortality in diabetic patients, when compared to other cellular- and tissue-based products". This study examines differences in ulcer occurrence and mortality for Medicare Diabetic Foot Ulcer (DFU) patients receiving cryopreserved placental membrane containing viable cells and other cellular and tissue-based products. The study's strict DFU definition which excludes beneficiaries without foot ulcer with demonstrated diabetes etiology makes it an innovative study. Suggested citation: DaVanzo J, Hartzman A, Surfield C, Dobson A. Cryopreserved placental membrane allograft reduces the likelihood of developing a new or recurring foot ulcer and all-cause mortality in diabetic patients, when compared to other cellular- and tissue-based products. Adv Wound Care (New Rochelle). 2022 Mar 9. doi: 10.1089/wound.2021.0123. Epub ahead of print. PMID: 35262428.